Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omega-3s and Alzheimer’s

This article was originally published in The Tan Sheet

Executive Summary

Omega-3 fatty acid supplementation may slow cognitive decline in some patients with very mild Alzheimer's disease (AD), according to a study in the October Archives of Neurology. While supplementation of DHA and EPA in patients with mild to moderate AD did not delay the rate of cognitive decline, positive effects were observed in post hoc analyses of a small group of patients with the mildest impairment, Yvonne Freund-Levi, MD, Karolinska Institutet, Stockholm, Sweden, et al., conclude. Findings from the additional analyses "cannot serve as a basis for general recommendations for treatment of AD with dietary DHA-rich fish oil preparations," the researchers stress. Daily for six months, 89 patients took 1.7 g of DHA and 0.6 g of EPA while 85 patients took placebo in the randomized, double-blind, clinical trial. Following this first six-month period, all participants received fatty acid supplementation for an additional half-year period. Participants in the treatment arm received 2.8-fold more DHA than EPA because of data on deficiency of DHA in brains affected with Alzheimer's, the researchers state, noting that many omega-3 supplementation trials favor EPA...

You may also be interested in...



Higher DHA Intake Associated With Reduced Risk Of Dementia – JAMA Study

A higher level of DHA in the blood is associated with a 47% reduction in the risk of developing all-cause dementia, a study in the November Archives of Neurology finds

P&G Health, Hygiene Brands Ride Consumer ‘Trust’ To Sales Growth Amid Pandemic Uncertainty

“There’s a heightened need for products that deliver against health, hygiene and clean home concerns and a willingness to spend just a little bit more to ensure that I’m using a product that I know and trust,” says CFO Jon Moeller 

Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel